OverviewSuggest Edit

Cardiorentis is a biopharmaceutical company, developing drug therapies for the treatment of acute heart failure and related cardiovascular diseases. The Company develops TRUE-AHF, an ularitide, which is an intravenous infusion treatment for acute heart failure; and SIRIUS I and II, a safety and efficacy study of an intravenous placebo controlled randomized infusion of ularitide in a prospective double–blind study in patients with symptomatic and decompensated chronic heart failures. Its disease-based technology platform includes protein biology to identify novel targets; design small molecule compounds and peptides for healthcare markets.


Key People/Management at Cardiorentis

Reto Wittwer

Reto Wittwer

Executive Vice President & Chief Financial Officer (CFO)
Stefan Mazgareanu

Stefan Mazgareanu

Senior Vice President & Chief Operating Officer (COO)
Markus Meyer

Markus Meyer

Senior Vice President & Chief Medical Officer (CMO)
Hanns-Eberhard Erle

Hanns-Eberhard Erle

Senior Vice President & Head of Global Supply
Johannes Holzmeister

Johannes Holzmeister

Chairman & Chief Executive Officer (CEO)
Alexander Goubarev

Alexander Goubarev

Non-Executive Director
Show more

Cardiorentis Office Locations

Cardiorentis has an office in Zug
Zug, CH (HQ)
74 Steinhauserstrasse
Show all (1)

Cardiorentis Financials and Metrics

Summary Metrics

Cardiorentis total Funding

$118.5 m

Cardiorentis investors

Cardiorentis Online and Social Media Presence

Embed Graph

Cardiorentis News and Updates

Acute Heart Failure (AHF) Therapeutics Market Status, Size (Value and Volume) By Manufacturers, Type, Application, And Region 2018-2026 | Top Players Pfizer Inc., Novartis AG, Cardiorentis AG, Amgen Inc., Bayer AG, Merck & Company, Inc.

The global acute heart failure therapeutics market is expected to witness significant growth due to the approval of new drugs. Posted via Industry Today. Follow us on Twitter @IndustryToday

Cardiorentis Frequently Asked Questions

  • Who are Cardiorentis key executives?

    Cardiorentis's key executives are Reto Wittwer, Stefan Mazgareanu and Markus Meyer.

  • Who are Cardiorentis competitors?

    Competitors of Cardiorentis include CTI BioPharma, Acticor Biotech and Palatin Technologies.

  • Where is Cardiorentis headquarters?

    Cardiorentis headquarters is located at 74 Steinhauserstrasse, Zug.

  • Where are Cardiorentis offices?

    Cardiorentis has an office in Zug.

  • How many offices does Cardiorentis have?

    Cardiorentis has 1 office.